Author(s): Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F, Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F
Abstract Share this page
Abstract This article reviews the role of CD20 antigen in B cell function and the effectiveness and limits of passive immunotherapy with anti-CD20 monoclonal antibody (Rituximab) in the treatment of autoimmune (or immune-mediated) diseases. Active immunotherapy is a more feasible way to control these chronic diseases. A peptide that mimics the CD20 epitope recognized by Rituximab is employed to stimulate the host immune response against CD20.
This article was published in Autoimmun Rev
and referenced in Immunome Research